-22.2%
DKNG vs MRNA
+34.8%
-57.0%
-61.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.3% | +5.4% | -1.0% | +4.0% |
| 7D | +3.0% | -1.1% | +4.1% | +3.1% |
| 30D | -3.0% | +126.1% | -129.1% | -11.2% |
| 3M | -17.6% | +190.0% | -207.6% | -27.1% |
| 6M | -3.2% | +157.2% | -160.5% | -13.6% |
| YTD | -28.2% | +388.2% | -416.4% | -41.3% |
| 1Y | -46.1% | +467.0% | -513.1% | -57.2% |
| 3Y | -22.2% | +36.1% | -58.3% | -32.5% |
| All | -22.2% | +34.8% | -57.0% | -32.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling